Atualização em reações de hipersensibilidade aos anti-inflamatórios não esteroidais – Parte 2: manifestações clínicas, fenótipos, diagnóstico e manejo
Update on hypersensitivity reactions to nonsteroidal anti-inflammatory drugs – Part 2: clinical features, phenotypes, diagnosis, and management
Marcelo Vivolo Aun; Rosana Câmara Agondi; Diogo Costa Lacerda; Ullissis Pádua Menezes; Maria Inês Perelló Lopes Ferreira; Adriana Teixeira Rodrigues; Ana Carolina D'Onofrio-Silva; Tânia Maria Gonçalves Gomes; Luiz Alexandre Ribeiro da-Rocha; Denise Neiva Santos de Aquino; Fernanda Casares Marcelino; Gladys Queiroz; Maria Fernanda Malaman; Inês Cristina Camelo-Nunes; Mara Morelo Rocha Felix
Resumo
Os anti-inflamatórios não esteroidais (AINE) são os fármacos mais frequentemente associados a reações de hipersensibilidade (RH) na prática clínica. Na parte 2 dessa atualização sobre as RH aos AINE, discutiremos os aspectos clínicos dessas reações, com foco nos sinais e sintomas, como diferenciar os fenótipos clínicos, fazer a orientação desses pacientes e quando indicar procedimentos complementares, como testes cutâneos, de provocação e dessensibilização.
Palavras-chave
Abstract
Nonsteroidal anti-inflammatory drugs are a major cause of drug hypersensitivity reactions in clinical practice. In this “Update Part 2”, we discuss the clinical picture, including the main signs and symptoms, how to distinguish clinical phenotypes, how to manage affected patients, and when to indicate additional procedures, such as skin testing, challenge, and desensitization.
Keywords
Referências
1. Aun MV, Agondi RC, Lacerda DC, Menezes UP, Perelló MI, Rodrigues AT, et al. Atualização em reações de hipersensibilidade aos antiinflamatórios não esteroidais – Parte 1: definições, farmacologia, epidemiologia, fisiopatologia e fatores genéticos. Arq Asma Alerg Imunol. 2022;6(3):307-17.
2. Kowalski ML, Makowska JS, Blanca M, Bavbek S, Bochenek G, Bousquet J, et al. Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) - classification, diagnosis and management: review of the EAACI/ENDA(#) and GA2LEN/HANNA*. Allergy. 2011;66(7):818-29.
3. Stevenson DD, Szczeklik A. Clinical and pathologic perspectives on aspirin sensitivity and asthma. Curr Rev Allergy Clin Immunol. 2016;118:773-86.
4. Stevenson DD, Sanchez-Borges M, Szczeklik A. Classification of allergic and pseudoallergic reactions to drugs that inhibit cyclooxigenase enzymes. Ann Allergy Asthma Immunol. 2001;87:177-80.
5. Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol. 2003;111:913-21.
6. Kowalski ML, Agache L, Bavbek S, Bakirtas A, Blanca M, Bochenek G, et al. Diagnosis and management of NSAID-exacerbated respiratory disease (NERD) – a EAACI position paper. Allergy. 2019;74:28-39.
7. Kowalski ML. Heterogeneity of NSAID-exacerbated respiratory disease: has the time come for subphenotyping? Curr Opin Pulm Med. 2019;25:64-70.
8. Rodríguez-Jiménez JC, Moreno-Paz FJ, Terán LM, Guaní-Guerra E. Aspirin exacerbated respiratory disease: current topics and trends. Respir Med. 2018;135:62-75.
9. Cardet JC, White AA, Barret NA, Feldweg AM, Wickner PG, Savage J, et al. Alcohol-induced respiratory symptoms are common in patients with aspirin exacerbated respiratory disease. J Allergy Clin Immunol. 2014;2:208-13.
10. Bochenek G, Kuschill-Dziurda J, Szafraniec K, Plutecka H, Szczeklik A, Nizankowska-Mogilnicka E. Certain subphenotypes of aspirinexacerbated respiratory disease distinguished by latente class analysis. J Allergy Clin Immunol. 2014;133:98-103.
11. Celejewska-Wójcik N, Wójcik K, Ignacak-Popiel M, Cmiel A, Tyrak K, Gielicz A, et al. Subphenotypes of nonsteroidal antiinflammatory disease-exacebated respiratory disease identified by latent class analysis. Allergy. 2019;75:831-40.
12. Sánchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A. Aspirinexacerbated cutaneous disease. Immunol Allergy Clin North Am. 2013;33(2):251-62.
13. Sánchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A, González-Aveledo L. Aspirin-exacerbated cutaneous disease (AECD) is a distinct subphenotype of chronic spontaneous urticaria. J Eur Acad Dermatol Venereol. 2015;29(4):698-701.
14. Doña I, Blanca-López N, Jagemann LR, Torres MJ, Rondón C, Campo P, et al. Response to a selective COX-2 inhibitor in patients with urticaria/angioedema induced by nonsteroidal anti-inflammatory drugs. Allergy. 2011;66(11):1428-33.
15. Kim YJ, Lim KH, Kim MY, Jo EJ, Lee SY, Lee SE, et al. Crossreactivity to Acetaminophen and Celecoxib According to the Type of Nonsteroidal Anti-inflammatory Drug Hypersensitivity. Allergy Asthma Immunol Res. 2014;6(2):156-62.
16. Sánchez-Borges M, Acevedo N, Caraballo L, CaprilesHulett A, Caballero-Fonseca F. Increased total and mitespecific immunoglobulin E in patients with aspirin-induced urticaria and angioedema. J Investig Allergol Clin Immunol. 2010;20(2):139‑45.
17. Doña I, Blanca-López N, Torres MJ, Gómez F, Fernández J, Zambonino MA, et al. NSAID-induced urticaria/angioedema does not evolve into chronic urticaria: a 12-year follow-up study. Allergy. 2014 Apr;69(4):438-44.
18. Asero R. Intolerance to nonsteroidal anti-inflammatory drugs might precede by years the onset of chronic urticaria. J Allergy Clin Immunol. 2003;111(5):1095-8.
19. Blanca-Lopez N, Soriano V, Garcia-Martin E, Canto G, Blanca M. NSAID-induced reactions: classification, prevalence, impact, and management strategies. J Asthma Allergy. 2019 Aug 8;12:217‑33.
20. Woessner KM, Castells M. NSAID single-drug-induced reactions. Immunol Allergy Clin North Am. 2013 May;33(2):237-49.
21. Demir S, Olgac M, Unal D, Gelincik A, Colakoglu B, Buyukozturk S. Evaluation of hypersensitivity reactions to nonsteroidal antiinflammatory drugs according to the latest classification. Allergy. 2015;70(11):1461-7.
22. Brockow K, Ardern-Jones MR, Mockenhaupt M, Aberer W, Barbaud A, Caubet JC, et al. EAACI position paper on how to classify cutaneous manifestations of drug hypersensitivity. Allergy. 2019;74(1):14-27.
23. Kowalski ML, Asero R, Bavbek S, Blanca M, Blanca-Lopez N, Bochenek G, et al. Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy. 2013 Oct;68(10):1219-32.
24. Doña I, Pérez-Sánchez N, Eguiluz-Gracia I, Muñoz-Cano R, Bartra J, Torres MJ, et al. Progress in understanding hypersensitivity reactions to nonsteroidal anti-inflammatory drugs. Allergy. 2020 Mar;75(3):561-75.
25. Tanno LK, Torres MJ, Castells M, Demoly P; Joint Allergy Academies. What can we learn in drug allergy management from World Health Organization's international classifications? Allergy. 2018;73(5):987‑92.
26. Doña I, Blanca-López N, Cornejo-García JA, Torres MJ, Laguna JJ, Fernández J, et al. Characteristics of subjects experiencing hypersensitivity to non-steroidal anti-inflammatory drugs: patterns of response. Clin Exp Allergy. 2011;41(1):86-95.
27. Doña I, Barrionuevo E, Salas M, Laguna JJ, Agúndez J, García-Martín E, et al. NSAIDs-hypersensitivity often induces a blended reaction pattern involving multiple organs. Sci Rep. 2018;8(1):16710.
28. Aun MV, Blanca M, Garro LS, Ribeiro MR, Kalil J, Motta AA, et al. Nonsteroidal anti-inflammatory drugs are major causes of drug-induced anaphylaxis. J Allergy Clin Immunol Pract. 2014;2(4):414‑20.
29. Giavina-Bianchi P, Aun MV, Jares EJ, Kalil J. Angioedema associated with nonsteroidal anti-inflammatory drugs. Curr Opin Allergy Clin Immunol. 2016;16(4):323-32.
30. Matsuo H, Morimoto K, Akaki T, Kaneko S, Kusatake K, Kuroda T, et al. Exercise and aspirin increase levels of circulating gliadin peptides in patients with wheat-dependent exercise-induced anaphylaxis. Clin Exp Allergy. 2005;35(4):461-6.
31. Sánchez-López J, Araujo G, Cardona V, García-Moral A, CasasSaucedo R, Guilarte M, et al. Food-dependent NSAID-induced hypersensitivity (FDNIH) reactions: Unraveling the clinical features and risk factors. Allergy. 2021;76(5):1480-92.
32. Pérez-Sánchez N, Bogas G, Cornejo-García JA, Andreu I, Doña I, Pérez-Alzate D, et al. Multiple nonsteroidal anti-inflammatory drug hypersensitivity without hypersensitivity to aspirin. J Allergy Clin Immunol Pract. 2016;4(3):524-5.
33. Bogas G, Pérez-Sánchez N, Andreu I, Doña I, Perkins JR, Blanca M, et al. Anaphylaxis to 2 NSAIDs in a Patient Who Tolerated ASA. J Investig Allergol Clin Immunol. 2016;26(4):266-8.
34. Guvenir H, Dibek Misirlioglu E, Vezir E, Toyran M, Ginis T, Civelek E, et al. Nonsteroidal anti-inflammatory drug hypersensitivity among children. Allergy Asthma Proc. 2015;36(5):386-93.
35. Pérez-Alzate D, Cornejo-García JA, Pérez-Sánchez N, Andreu I, García-Moral A, Agúndez JA, et al. Immediate Reactions to More Than 1 NSAID Must Not Be Considered Cross-Hypersensitivity Unless Tolerance to ASA Is Verified. J Investig Allergol Clin Immunol. 2017;27(1):32-9.
36. Blanca-López N, Bogas G, Doña I, Torres MJ, Blanca M, CornejoGarcía JA, et al. ASA must be given to classify multiple NSAIDhypersensitivity patients as selective or cross-intolerant. Allergy. 2016;71(4):576-8.
37. Yeung WYW, Park HS. Update on the Management of Nonsteroidal Anti-Inflammatory Drug Hypersensitivity. Yonsei Med J. 2020;61(1):4‑14.
38. Terzioğlu K, Sancar Ö, Ekerbiçer HÇ, Öztürk RT, Epöztürk K. Tolerability to paracetamol and preferential COX-2 inhibitors in patients with cross-reactive nonsteroidal anti-inflammatory drugs hypersensitivity. Asia Pac Allergy. 2020;10(3):e29.
39. Bavbek S, Celik G, Ozer F, Mungan D, Misirligil Z. Safety of selective COX-2 inhibitors in aspirin/nonsteroidal anti-inflammatory drugintolerant patients: comparison of nimesulide, meloxicam, and rofecoxib. J Asthma. 2004;41(1):67-75.
40. Senna G, Bilò MB, Antonicelli L, Schiappoli M, Crivellaro MA, Bonadonna P, et al. Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients. Eur Ann Allergy Clin Immunol. 2004;36(6):215-8.
41. Corzo JL, Zambonino MA, Muñoz C, Mayorga C, Requena G, Urda A, et al. Tolerance to COX-2 inhibitors in children with hypersensitivity to nonsteroidal anti-inflammatory drugs. Br J Dermatol. 2014;170(3):725-9.
42. Kim YJ, Lim KH, Kim MY, Jo EJ, Lee SY, Lee SE, et al. Crossreactivity to Acetaminophen and Celecoxib According to the Type of Nonsteroidal Anti-inflammatory Drug Hypersensitivity. Allergy Asthma Immunol Res. 2014 Mar;6(2):156-62.
43. Zanandrea A, Mouco CC, Assis JP, Dias GMFS, Castro RB, Brugnoll RM, et al. Hypersensitivity to paracetamol: placebo effect or overdiagnosis? J Allergy Clin Immunol. 2017;141(2):AB43.
44. Li L, Laidlaw T. Cross-reactivity and tolerability of celecoxib in adult patients with NSAID hypersensitivity. J Allergy Clin Immunol Pract. 2019;7(8):2891-3.
45. El-Malah AA, Gineinah MM, Deb PK, Khayyat AN, Bansal M, Venugopala KN, et al. Selective COX-2 Inhibitors: Road from Success to Controversy and the Quest for Repurposing. Pharmaceuticals (Basel). 2022;15(7):827.
46. Lutfeali S, Khan DA. Pediatric Drug Allergies. Update on Beta-lactam, Nonsteroidal Anti-Inflammatory Drug, and Chemotherapeutic Reactions. Pediatr Clin N Am. 2019;66:1035-51.
47. Kidon M, Blanca-Lopez N, Gomes E, Terreehorst I, Tanno L, Ponvert C, et al. EAACI/ENDA Position Paper: Diagnosis and management of hypersensitivity reactions to non-steroidal anti-inflammatory drugs (NSAIDs) in children and adolescents. Pediatr Allergy Immunol. 2018;29(5):469-80.
48. Rubio M, Bousquet PJ, Gomes E, Romano A, Demoly P. Results of drug hypersensitivity evaluations in a large group of children and adults. Clin Exp Allergy. 2012;42(1):123-30.
49. Mori F, Atanaskovic-Markovic M, Blanca-Lopez N, Gomes E, Gaeta F, Sarti L, et al. A Multicenter Retrospective Study on Hypersensitivity Reactions to Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) in Children: A Report from the European Network on Drug Allergy (ENDA) Group. J Allergy Clin Immunol Pract. 2020;8(3):1022-31.
50. Cousin M, Chiriac A, Molinari N, Demoly P, Caimmi D. Phenotypical characterization of children with hypersensitivity reactions to NSAIDs. Pediatr Allergy Immunol. 2016;27(7):743-8.
51. Gómez E, Blanca-Lopez N, Torres MJ, Requena G, Rondon C, Canto G, et al. Immunoglobulin E-mediated immediate allergic reactions to dipyrone: value of basophil activation test in the identification of patients. Clin Exp Allergy. 2009 Aug;39(8):1217-24.
52. Decuyper II, Mangodt EA, Van Gasse AL, Claesen K, Uyttebroek A, Faber M, et al. In Vitro Diagnosis of Immediate Drug Hypersensitivity Anno 2017: Potentials and Limitations. Drugs R D. 2017;17:265‑78.
53. Zambonino MA, Torres MJ, Muñoz C, Requena G, Mayorga C, Posadas T, et al. Drug provocation tests in the diagnosis of hypersensitivity reactions to non-steroidal anti-inflammatory drugs in children. Pediatr Allergy Immunol. 2013;24(2):151-9.
54. Yilmaz O, Ertoy Karagol IH, Bakirtas A, Topal E, Celik GE, Demirsoy MS, et al. Challenge-proven nonsteroidal anti-inflammatory drug hypersensitivity in children. Allergy. 2013;68(12):1555-61.
55. Ertoy Karagol HI, Yilmaz O, Topal E, Ceylan A, Bakirtas A. Nonsteroidal anti-inflammatory drugs-exacerbated respiratory disease in adolescents. Int Forum Allergy Rhinol. 2015;5(5):392-8.
56. Kidon MI, Liew WK, Chiang WC, Lim SH, Goh A, Tang JP, et al. Hypersensitivity to paracetamol in Asian children with early onset of nonsteroidal anti-inflammatory drug allergy. Int Arch Allergy Immunol. 2007;144(1):51-6.
57. Loh W, Lim HH, Rao R, Goh A, Ong LX, Chiang WC. Tolerance to etoricoxib in children with nonsteroidal anti-inflammatory drug hypersensitivity. Asia Pac Allergy. 2015;5(1):40-6.
58. Simsek IE, Cogurlu MT, Aydogan M. Two approaches for diagnosis of nonsteroidal anti-inflammatory drug hypersensitivity in children. Ann Allergy Asthma Immunol. 2019;123:389-93.
59. Blanca-López N, Haroun-Diaz E, Ruano FJ, Pérez-Alzate D, Somoza ML, Vázquez de la Torre Gaspar M, et al. Acetyl Salicylic Acid Challenge in Children with Hypersensitivity Reactions to Nonsteroidal Anti-Inflammatory Drugs Differentiates Between Cross-Intolerant and Selective Responders. J Allergy Clin Immunol Pract. 2018;6(4):1226-35.
60. Aun MV, Kalil J, Giavina-Bianchi P. Drug-Induced Anaphylaxis. Immunol Allergy Clin North Am. 2017;37(4):629-41.
61. Khan DA, Banerji A, Blumenthal KG, Phillips EJ, Solensky R, White AA, et al. Drug Allergy: A 2022 Practice Parameter Update. J Allergy Clin Immunol. 2022:S0091-6749(22)01186-1.
62. Cahill KN. Immunologic effects of aspirin desensitization abd highdose aspirin therapy in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2021;148:344-7.
63. Woessner KM. Aspirin desensitization for cardiovascular disease. Curr Opin Allergy Clin Immunol. 2015;15:314-22.
64. Giavina-Bianchi P, Aun MV, Galvão VR, Castells M. Rapid Desensitization in Immediate Hypersensitivity Reaction to Drugs. Curr Treat Options Allergy. 2015;2:268-85.
65. White AA, Stevenson DD. Aspirin-exacerbated respiratory disease. N Engl J Med. 2018;379:1060-70.
66. Katial RK, Strand M, Prasertsuntarasai T, Leung R, Zheng W, Alam R. The effect of aspirin desensitization on novel biomarkers in aspirin-exacerbated respiratory diseases. J Allergy Clin Immunol. 2012;126:738-44.
67. Simon RA. Diagnostic challenge and desensitization protocols for NSAID reactions. UpToDate.com. Literature review current through: Sep. 2022.
68. Benito-Garcia F, Pires I, Lima J. Aspirin Desensitization: Implications for Acetylsalicylic Acid-Sensitive Pregnant Women. Medicina (Kaunas). 2021;57(4):390.
69. Mkhize PZ, Phoswa WN, Khaliq OP, Dorsamy V, Moodley J. Aspirin in the prevention of preeclampsia: A protocol for systematic review and meta-analysis. Medicine (Baltimore). 2021;100(48):e27916.
Submetido em:
27/10/2022
Aceito em:
04/11/2022
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email